Measuring the outcome of clinical trials

Several arrows have fallen short of their target, which is a pill on a bullseye. This image suggests that a drug targeted towards autism's symptoms has not yet been made.

Why don’t we have better drugs for autism?

by Rachel Zamzow / 15 February 2017

Clinical trials for autism drugs have been plagued with problems: bad design, the wrong measures, too broad a range of participants. All that is finally starting to change.

Questions for Gahan Pandina: New tool may aid autism trials

by Nicholette Zeliadt / 14 February 2017

A new ‘knowledge engine’ collects reams of behavioral and sensory data to create highly sensitive outcome measures for autism drugs.

Despite setbacks, fragile X drugs file into clinical trials

by Jessica Wright / 30 November 2016

Our infographic displays efforts to develop treatments for fragile X syndrome. So far, none of them have passed muster in clinical trials.

Featured Articles

Why don’t we have better drugs for autism?

Questions for Gahan Pandina: New tool may aid autism trials

Despite setbacks, fragile X drugs file into clinical trials

From The Archives

The innovators: How families launch their own autism studies

Questions for James McPartland: Biomarkers for better trials

Devising spectrum of tests for different types of autism

Better behavioral tests may save trials of autism treatments

Some people in ‘failed’ drug trial for autism showed benefit

Questions for Eric Klann: Translating treatments for fragile X

Why trials of autism treatments have a placebo problem

Jeremy Veenstra-VanderWeele talks routes to treatment

Questions for Elizabeth Berry-Kravis: Measuring drug effects

Better tools needed to assess clinical trials

Spectrum: Autism Research News

Measuring the outcome of clinical trials

Featured Articles

From The Archives